New treatment approach for gliomas with IDH1 mutations
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy
['FUNDING_R01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-11070351
This study is exploring a new treatment for aggressive brain tumors with IDH1 gene mutations, aiming to find out how a special class of drugs can help kill these cancer cells, which could lead to better options for patients facing this tough condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11070351 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel therapy for gliomas, particularly those with mutations in the IDH1 gene, which are common in aggressive brain tumors. The team has identified a class of drugs that target a specific metabolic pathway, leading to the death of tumor cells with these mutations. By studying both cultured brain tumor cell lines and organoid models derived from human glioma tissue, the researchers aim to understand how IDH1 mutations make these tumors more susceptible to treatment. This approach could pave the way for more effective therapies for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with gliomas that have IDH1 mutations.
Not a fit: Patients with gliomas that do not have IDH1 mutations may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that significantly improve outcomes for patients with IDH1 mutant gliomas.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCBRAYER, SAMUEL KENT — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: MCBRAYER, SAMUEL KENT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy